Supercharged by Social Media, the GLP-1 Boom Is Warping Teen Psyches
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Supercharged by Social Media, the GLP-1 Boom Is Warping Teen Psyches" is generating significant coverage in the Health category, with 4 articles from 4 distinct sources tracked by PULSE so far.
Outlets currently covering the story include ConsumerAffairs, YPulse, MDLinx and Bloomberg.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 97d ago.
Quick answers
Why is "Supercharged by Social Media, the GLP-1 Boom Is Warping Teen Psyches" trending?
Because 4 independent news sources published 4 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (4)
- GLP-1 drugs are changing how teens and young adults treat obesity ConsumerAffairs · 100d ago
- Are Teens and Young Adults Actually Using GLP-1s? YPulse · 100d ago
- The pediatric GLP-1 dilemma at summer camp MDLinx · 100d ago
- Supercharged by Social Media, the GLP-1 Boom Is Warping Teen Psyches Bloomberg.com · 100d ago
Topics
Related trends
GLP-1 poison calls surge in Georgia as experts warn about unapproved weight-loss drugs - WSB-TV
Georgia poison centers report a surge in calls linked to GLP-1 weight-loss drugs as experts flag risks from unapproved versions.
Should you take GLP-1s during pregnancy? What some doctors say.
New research on GLP-1 drugs during pregnancy sparks urgent debate among doctors and patients.
Tracking China’s War of Words Against Japan
Recent reporting tracks an expanding campaign by China involving transnational repression and cognitive warfare targeting Japan.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New Cleveland Clinic research maps five evidence-based exit strategies for patients discontinuing GLP-1 weight-loss drugs, a question facing millions as supply and cost pressures mount.